MA49140A - Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques - Google Patents

Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques

Info

Publication number
MA49140A
MA49140A MA049140A MA49140A MA49140A MA 49140 A MA49140 A MA 49140A MA 049140 A MA049140 A MA 049140A MA 49140 A MA49140 A MA 49140A MA 49140 A MA49140 A MA 49140A
Authority
MA
Morocco
Prior art keywords
heteroaromatic
merged
treatment
aniline compounds
dermal disorders
Prior art date
Application number
MA049140A
Other languages
English (en)
Inventor
Matthew Duncton
John Kincaid
Original Assignee
Nflection Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nflection Therapeutics Inc filed Critical Nflection Therapeutics Inc
Publication of MA49140A publication Critical patent/MA49140A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4355—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having oxygen as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4365—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system having sulfur as a ring hetero atom, e.g. ticlopidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pyridine Compounds (AREA)
MA049140A 2017-05-19 2018-05-18 Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques MA49140A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762508997P 2017-05-19 2017-05-19

Publications (1)

Publication Number Publication Date
MA49140A true MA49140A (fr) 2020-03-25

Family

ID=62620965

Family Applications (1)

Application Number Title Priority Date Filing Date
MA049140A MA49140A (fr) 2017-05-19 2018-05-18 Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques

Country Status (13)

Country Link
US (2) US10988483B2 (fr)
EP (1) EP3624795B1 (fr)
JP (1) JP7237941B2 (fr)
KR (1) KR102659322B1 (fr)
CN (1) CN111093658B (fr)
AU (1) AU2018270292B2 (fr)
CA (1) CA3063535A1 (fr)
DK (1) DK3624795T3 (fr)
ES (1) ES2913213T3 (fr)
IL (1) IL270576B (fr)
MA (1) MA49140A (fr)
MX (1) MX2019013562A (fr)
WO (1) WO2018213807A1 (fr)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3624795B1 (fr) 2017-05-19 2022-04-20 NFlection Therapeutics, Inc. Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA55148A (fr) * 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés d'aryl-aniline et d'hétéroaryl-aniline pour le traitement de marques de naissance
CA3120337A1 (fr) 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes naphthyridinone-aniline destines au traitement d'affections de la peau
CA3120351A1 (fr) * 2018-11-20 2020-05-28 Nflection Therapeutics, Inc. Composes aryl-aniline et heteroaryl-aniline pour le traitement de cancers de la peau
MA55141A (fr) 2018-11-20 2021-09-29 Nflection Therapeutics Inc Composés cyanoaryl-aniline pour le traitement d'affections de la peau
JP7546297B2 (ja) 2018-11-20 2024-09-06 エヌフレクション セラピューティクス インコーポレイテッド 皮膚障害の処置のためのチエニル－アニリン化合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3536809A (en) 1969-02-17 1970-10-27 Alza Corp Medication method
US3598123A (en) 1969-04-01 1971-08-10 Alza Corp Bandage for administering drugs
US3845770A (en) 1972-06-05 1974-11-05 Alza Corp Osmatic dispensing device for releasing beneficial agent
US3916899A (en) 1973-04-25 1975-11-04 Alza Corp Osmotic dispensing device with maximum and minimum sizes for the passageway
US4008719A (en) 1976-02-02 1977-02-22 Alza Corporation Osmotic system having laminar arrangement for programming delivery of active agent
ES8702440A1 (es) 1984-10-04 1986-12-16 Monsanto Co Un procedimiento para la preparacion de una composicion de polipeptido inyectable sustancialmente no acuosa.
IE58110B1 (en) 1984-10-30 1993-07-14 Elan Corp Plc Controlled release powder and process for its preparation
US5073543A (en) 1988-07-21 1991-12-17 G. D. Searle & Co. Controlled release formulations of trophic factors in ganglioside-lipsome vehicle
IT1229203B (it) 1989-03-22 1991-07-25 Bioresearch Spa Impiego di acido 5 metiltetraidrofolico, di acido 5 formiltetraidrofolico e dei loro sali farmaceuticamente accettabili per la preparazione di composizioni farmaceutiche in forma a rilascio controllato attive nella terapia dei disturbi mentali organici e composizioni farmaceutiche relative.
PH30995A (en) 1989-07-07 1997-12-23 Novartis Inc Sustained release formulations of water soluble peptides.
US5120548A (en) 1989-11-07 1992-06-09 Merck & Co., Inc. Swelling modulated polymeric drug delivery device
US5733566A (en) 1990-05-15 1998-03-31 Alkermes Controlled Therapeutics Inc. Ii Controlled release of antiparasitic agents in animals
US5580578A (en) 1992-01-27 1996-12-03 Euro-Celtique, S.A. Controlled release formulations coated with aqueous dispersions of acrylic polymers
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US5591767A (en) 1993-01-25 1997-01-07 Pharmetrix Corporation Liquid reservoir transdermal patch for the administration of ketorolac
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
IT1270594B (it) 1994-07-07 1997-05-07 Recordati Chem Pharm Composizione farmaceutica a rilascio controllato di moguisteina in sospensione liquida
WO1997001331A2 (fr) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Production de preparations a liberation prolongee
TW448055B (en) 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
JP2909418B2 (ja) 1995-09-18 1999-06-23 株式会社資生堂 薬物の遅延放出型マイクロスフイア
US5980945A (en) 1996-01-16 1999-11-09 Societe De Conseils De Recherches Et D'applications Scientifique S.A. Sustained release drug formulations
US6264970B1 (en) 1996-06-26 2001-07-24 Takeda Chemical Industries, Ltd. Sustained-release preparation
US6419961B1 (en) 1996-08-29 2002-07-16 Takeda Chemical Industries, Ltd. Sustained release microcapsules of a bioactive substance and a biodegradable polymer
CA2217134A1 (fr) 1996-10-09 1998-04-09 Sumitomo Pharmaceuticals Co., Ltd. Formulation a liberation-retard
EP0839525B1 (fr) 1996-10-31 2004-08-04 Takeda Chemical Industries, Ltd. Préparation à libération retardée
DE69719367T2 (de) 1996-12-20 2003-10-16 Takeda Chemical Industries, Ltd. Verfahren zur herstellung einer zusammensetzung mit verzoegerter abgabe
US5891474A (en) 1997-01-29 1999-04-06 Poli Industria Chimica, S.P.A. Time-specific controlled release dosage formulations and method of preparing same
US6613358B2 (en) 1998-03-18 2003-09-02 Theodore W. Randolph Sustained-release composition including amorphous polymer
KR19990085365A (ko) 1998-05-16 1999-12-06 허영섭 지속적으로 약물 조절방출이 가능한 생분해성 고분자 미립구 및그 제조방법
US6248363B1 (en) 1999-11-23 2001-06-19 Lipocine, Inc. Solid carriers for improved delivery of active ingredients in pharmaceutical compositions
US7674907B2 (en) * 2004-07-23 2010-03-09 Amgen Inc. Furanopyridine derivatives and methods of use
AU2006210787C1 (en) 2005-02-02 2013-01-17 Nexgenix Pharmaceuticals, L.L.C. Local treatment of neurofibromas
PL2395004T3 (pl) 2005-06-22 2016-08-31 Plexxikon Inc Pochodne pirolo[2,3-b]pirydyny jako inhibitory kinazy białkowej
GB0601962D0 (en) * 2006-01-31 2006-03-15 Ucb Sa Therapeutic agents
GB0616214D0 (en) 2006-08-15 2006-09-27 Ucb Sa Therapeutic Agents
EP2069354B1 (fr) * 2006-08-21 2011-11-02 Genentech, Inc. Composés aza-benzofuranyle et leurs procédés d'utilisation
MX2009001875A (es) * 2006-08-21 2009-03-02 Genentech Inc Compuestos de aza-benzotiofenilo y metodos de uso de los mismos.
WO2008055236A2 (fr) 2006-10-31 2008-05-08 Takeda Pharmaceutical Company Limited Inhibiteurs de kinase mapk/erk
CL2007003444A1 (es) 2006-11-30 2008-06-27 Genentech Inc Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria.
WO2008148034A1 (fr) 2007-05-25 2008-12-04 Takeda Pharmaceutical Company Limited Inhibiteurs de mapk/erk kinase
GB0714384D0 (en) * 2007-07-23 2007-09-05 Ucb Pharma Sa theraputic agents
NZ586575A (en) 2007-12-21 2012-03-30 Genentech Inc Azaindolizines and methods of use
GB0801081D0 (en) * 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
EP2240494B1 (fr) 2008-01-21 2016-03-30 UCB Biopharma SPRL Dérivés de thiénopyridine utilisés comme inhibiteurs de mek
GB0801080D0 (en) 2008-01-21 2008-02-27 Ucb Pharma Sa Therapeutic agents
GB0811304D0 (en) 2008-06-19 2008-07-30 Ucb Pharma Sa Therapeutic agents
JP2010043019A (ja) * 2008-08-12 2010-02-25 Taisho Pharmaceutical Co Ltd ピペリジニルピペラジン化合物
US8324239B2 (en) * 2010-04-21 2012-12-04 Novartis Ag Furopyridine compounds and uses thereof
WO2012040636A2 (fr) 2010-09-24 2012-03-29 The Broad Institute, Inc. Composés et méthodes de traitement de maladies à médiation par des récepteurs activés par une protéase
WO2014179785A1 (fr) 2013-05-03 2014-11-06 Inscent, Inc. Répulsifs améliorés contre les abeilles domestiques et leurs utilisations
CN105384754B (zh) 2014-09-02 2018-04-20 上海科州药物研发有限公司 作为蛋白激酶抑制剂的杂环类化合物及其制备方法和用途
ES3030506T3 (en) 2017-05-19 2025-06-30 Nflection Therapeutics Inc Pyrrolopyridine-aniline compounds for treatment of dermal disorders
EP3624795B1 (fr) 2017-05-19 2022-04-20 NFlection Therapeutics, Inc. Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques

Also Published As

Publication number Publication date
CN111093658A (zh) 2020-05-01
US20200172550A1 (en) 2020-06-04
CA3063535A1 (fr) 2018-11-22
EP3624795B1 (fr) 2022-04-20
MX2019013562A (es) 2020-08-03
US11542271B2 (en) 2023-01-03
AU2018270292B2 (en) 2022-02-10
AU2018270292A1 (en) 2019-12-05
EP3624795A1 (fr) 2020-03-25
DK3624795T3 (da) 2022-05-23
CN111093658B (zh) 2022-10-14
JP7237941B2 (ja) 2023-03-13
WO2018213807A1 (fr) 2018-11-22
IL270576B (en) 2022-01-01
JP2020520994A (ja) 2020-07-16
ES2913213T3 (es) 2022-06-01
KR20200026812A (ko) 2020-03-11
US20210380601A1 (en) 2021-12-09
US10988483B2 (en) 2021-04-27
KR102659322B1 (ko) 2024-04-22

Similar Documents

Publication Publication Date Title
EP3704108A4 (fr) Composés et compositions pour le traitement de troubles hématologiques
MA47719A (fr) Esketamine pour le traitement de la dépression
EP3340982A4 (fr) Composés pour le traitement de troubles immunitaires et inflammatoires
EP3448398A4 (fr) Compositions et méthodes pour le traitement de troubles cutanés
EP3570844A4 (fr) Azolopyrimidine pour le traitement de troubles liés au cancer
EP3013345A4 (fr) Composés pour le traitement d'une amyotrophie spinale
MA45481A (fr) Utilisation d'exosomes pour le traitement de maladies
EP3352749A4 (fr) Composés et compositions pour le traitement de troubles oculaires
EP3411380A4 (fr) Composés destinés au traitement de troubles ou de maladies oculaires
MA49140A (fr) Composés hétéroaromatiques-aniline fusionnés pour le traitement de troubles dermiques
MA44875A (fr) Compositions pour le traitement de troubles acido-basiques
EP3621973A4 (fr) Composés pour la prévention et le traitement de maladies et leur utilisation
EP3328864A4 (fr) Composés et compositions thérapeutiques pour le traitement de troubles sociaux et de troubles liés à la toxicomanie
MA44737A (fr) Compositions pour le traitement de troubles liés à l'hyperkératose
EP3630102A4 (fr) Formulations pour le traitement d'un trouble de stress post-traumatique
EP3774743C0 (fr) Composés de type promédicaments activés par akr1c3 et leur utilisation pour le traitement de troubles hyperprolifératifs
MA51672A (fr) Composés destinés au traitement des troubles kinases-dépendants
MA47212A (fr) Méthodes de traitement de troubles neurologiques
MA51738A (fr) Composés pour le traitement de la douleur
EP3352755A4 (fr) Nouveaux composés, compositions et méthodes pour le traitement de troubles cutanés
MA55218A (fr) Eskétamine pour le traitement de la dépression
EP3621434A4 (fr) Méthodes de traitement de troubles neuropsychiatriques
MA47207A (fr) Composés utiles pour le traitement de troubles du tractus digestif
EP3606542A4 (fr) Protéines pour le traitement de troubles de la fonction barrière épithéliale
MA39927A (fr) Inhibiteurs de glyt1 pour le traitement de troubles hématologiques